IRB ACTION OPTIONS

A – Approved. **Acceptable as is.** NO changes are required.

M – Minor changes required. **Specific, non-substantial revisions are required.** Member comments must be directive requesting simple concurrences or specific, non-substantial changes. Upon receipt of the required changes, the IRB Chair or another member designated by the Chair will verify that the appropriate additions/corrections were made and will approve the study.

T – Tabled for re-review. **Substantial revisions and/or additional information (e.g., details, clarification, justifications) are required that are directly relevant to the Criteria for IRB approval.** Tabling a protocol requires that the study with the inclusion of additional information or revisions be reviewed by the Board at a convened meeting.

D – Disapproved. The IRB may disapprove the study. This is only done after multiple attempts have been made to resolve the issues including, at the discretion of the IRB, inviting the Investigator to the Board meeting.
In order to approve research covered by these regulations (45 CFR 46.111 and 21 CFR 56.111) the IRB shall determine that all of the following requirements are satisfied:

1. **Risks to subjects are minimized** by using procedures which are consistent with sound research design and that do not unnecessarily expose subjects to risk, and whenever appropriate, by using procedures already being performed on the subjects for diagnostic or treatment purposes (Beneficence).

2. **Risks to subjects are reasonable in relation to anticipated benefits**, if any, to subjects, and the importance of the knowledge that may reasonably be expected to result. In evaluating risks and benefits, the IRB should consider only those risks and benefits that may result from the research, as distinguished from risks and benefits of therapies subjects would receive even if not participating in the research (Beneficence).

3. **Selection of subjects is equitable**. In making this assessment the IRB should take into account the purposes of the research and the setting in which the research will be conducted. The IRB should be particularly cognizant of the special problems of research that involves a category of subjects who are vulnerable to coercion or undue influence, such as children, prisoners, individuals with impaired decision-making capacity, or economically or educationally disadvantaged persons (Justice).\(^1\)

4. **Informed consent** will be sought from each prospective subject or the subject’s legally authorized representative, in accordance with, and to the extent required by the Federal regulations (Respect for Persons).

5. Informed consent will be appropriately **documented** (or appropriately waived\(^2\)) in accordance with, and to the extent required by the Federal regulations (Respect for Persons).

6. When appropriate, the research plan makes adequate provision for monitoring the data collected to assure the safety of subjects (Beneficence).

7. When appropriate, there are adequate provisions to protect the privacy of subjects and to maintain the confidentiality of data (Respect for Persons and Beneficence).

b) When some or all of the subjects are likely to be vulnerable to coercion or undue influence, such as children, prisoners, individuals with impaired decision-making capacity, or economically or educationally disadvantaged persons, additional safeguards have been included in the study to protect the rights and welfare of these subjects (Respect for Persons and Beneficence)\(^3\).

---

\(^1\) January 21, 2019: The 2018 Common Rule removes pregnant women as ‘vulnerable’ however Subpart B still applies.

\(^2\) OHRP 45 CFR 46.111 / FDA will allow waivers or alterations of consent for research no more than minimal risk as per [FDA guidance document](https://www.fda.gov/规制指南) dated July 2017.

\(^3\) Per FDA 21 CFR 56.111 pregnant women are listed as part of vulnerable populations and individuals with impaired decision-making capacity are listed as mentally disabled persons.
Determining Whether Human Subject Research Can be Conducted Without an IND

The following is provided in part from this FDA Guidance.

The FDA states in 21 CFR 312 that human subject research studies must be conducted under an investigational new drug application if the following conditions exist:

1. **Is it a Drug?**
   - Is it defined in section 201(g)(1) of the Federal Food, Drug, and Cosmetic Act (the FD&C Act) (21 U.S.C. 321(g)(1))?  
     - a. Is it an article intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease?  
     - b. Is it an article (other than food and dietary supplements, addressed in # 2 below) intended to affect the structure or any function of the body of man or other animals?

2. **Is it a Dietary Supplement?**
   - Under the Dietary Supplement Health and Education Act of 1994 (DSHEA), a dietary supplement is not a drug if the intended use for which it is marketed is only to affect or evaluate the effect of the structure or any function of the body (i.e., not intended to be used for a therapeutic purpose).  
     - a. If the intent is to evaluate the dietary supplement’s ability to diagnose, cure, mitigate, treat, or prevent a disease, an IND is required under part 21 CFR 312.

3. **Is it a Biological Product?**
   - Is it a virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product, protein (except any chemically synthesized polypeptide), or analogous product, or arsphenamine or derivative of arsphenamine (or any other trivalent organic arsenic compound), applicable to the prevention, treatment, or cure of a disease or condition of human beings?

If either 1a, 1b, 3a are TRUE, go to 4!

4. **Is it a Clinical Investigation as defined in the IND regulations (21 CFR 312.3)?**
   - a. Is it an experiment? i.e. any use of a drug [whether approved or unapproved] except for the use of a marketed drug in the course of medical practice?  
   - b. Is it an experiment in which a drug or biological product is administered or dispensed to, or used involving one or more human subjects?

If either 4a or 4b are TRUE, GO to 5 or 6!

5. **Is it exempt from IND requirements?**  
   - **If ALL of the following are true, then an IND is NOT required:**  
     - a. The drug product is lawfully marketed in the United States.  
     - b. The investigation is not intended to be reported to FDA as a well-controlled study in support of a new indication and there is no intent to use it to support any other significant change in the labeling of the drug.  
     - c. In the case of a prescription drug, the investigation is not intended to support a significant change in the advertising for the drug.  
     - d. The investigation does not involve a route of administration, dose, patient population, or other factor that significantly increases the risk (or decreases the acceptability of the risk) associated with the use of the drug product (21 CFR 312.2(b)(1)(iii)).  
     - e. The investigation is conducted in compliance with the requirements for review by an IRB (21 CFR part 56) and with the requirements for informed consent (21 CFR part 50).  
     - f. The investigation is conducted in compliance with the requirements of 21 CFR 312.7 (i.e., the investigation is not intended to promote or commercialize the drug product).

6. **Is it exempt from IND requirements?**  
   - **If ALL of the following are true, then an IND is NOT required:**  
     - a. The studies are not intended to support FDA approval of a new indication or a significant change in the product labeling  
     - b. The studies are not intended to support a significant change in the advertising for the product.  
     - c. Investigators and their IRBs determine that based on the scientific literature and generally known clinical experience, there is no significant increase in the risk associated with the use of the drug product.  
     - d. The studies are to be conducted in compliance with IRB and informed consent regulations, pursuant to parts 50 and 56.  
     - e. The studies will not be used to promote unapproved indications, in compliance with 21 CFR 312.

**FDA has issued guidance** to help clinical investigators studying cancer treatments determine whether the risk associated with the use of the drug in a planned clinical investigation is significantly increased or the acceptability of the risk is significantly decreased.
Determining Whether Human Subject Research Can be Conducted Without an IND

A Few Additional Points to Consider:

Off Label Use for Research: A Few Notes from Jeff Cooper, M.D.:
When considering FDA approved drugs proposed off label, a best practice would be to start with the package insert. Is there a significant difference in the proposed use versus the package insert?

Per Dr. Cooper, in a 2021 presentation to the IRB and HRP, do not rely on the FDA to understand standard of care differences, science or even common sense when considering if an IND is needed or not.

The FDA will hold the IRB responsible if an IND is needed. If anything is unclear – have the investigator go to the FDA to confirm if an IND is needed. Provide the investigator resources to assist with the process, if possible. In the past, we have worked with Center for Clinical Research to provide aid to Faculty.

UCI IRB Example of When an IND Applied (Drug):

<table>
<thead>
<tr>
<th>IRB# 2659:</th>
<th>IND Needed</th>
</tr>
</thead>
<tbody>
<tr>
<td>Randomized, placebo-controlled study that will involve extending oral caffeine versus sterile water (placebo) treatment for at least 2-4 weeks after meeting criteria to discontinue caffeine, which is typically 5 days without significant cardiopulmonary events and at least 33-34 weeks corrected gestational age (CGA) to determine if additional caffeine will aid in better nippleling tolerance / feeding. FDA determined IND required.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>No IND Needed</th>
<th>IND Needed</th>
</tr>
</thead>
<tbody>
<tr>
<td>A clinical investigation designed to study the relationship between a dietary supplement's effect on normal structure or function in humans (e.g., guarana and maximal oxygen uptake) or to characterize the mechanism by which a dietary supplement acts to maintain such structure or function (e.g., fiber and bowel regularity)</td>
<td>A clinical investigation designed to evaluate a dietary supplement's ability to prevent osteoporosis or to treat chronic diarrhea or constipation</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>No IND Needed</th>
<th>IND Needed</th>
</tr>
</thead>
<tbody>
<tr>
<td>A clinical investigation designed to study the relationship between a dietary supplement's effect on normal structure or function in humans (e.g., guarana and maximal oxygen uptake) or to characterize the mechanism by which a dietary supplement acts to maintain such structure or function (e.g., fiber and bowel regularity)</td>
<td>A clinical investigation designed to evaluate a dietary supplement's ability to prevent osteoporosis or to treat chronic diarrhea or constipation</td>
</tr>
</tbody>
</table>

FDA Examples of When an IND May Apply:

<table>
<thead>
<tr>
<th>No IND Needed</th>
<th>IND Needed</th>
</tr>
</thead>
<tbody>
<tr>
<td>A clinical investigation designed to study the relationship between a dietary supplement's effect on normal structure or function in humans (e.g., guarana and maximal oxygen uptake) or to characterize the mechanism by which a dietary supplement acts to maintain such structure or function (e.g., fiber and bowel regularity)</td>
<td>A clinical investigation designed to evaluate a dietary supplement's ability to prevent osteoporosis or to treat chronic diarrhea or constipation</td>
</tr>
</tbody>
</table>

UCI IRB Examples of When an IND Applied (Supplements):

<table>
<thead>
<tr>
<th>IRB # 218:</th>
<th>IND Needed</th>
</tr>
</thead>
<tbody>
<tr>
<td>Assessing the effect of an educational prevention course, multivitamin, multi-mineral intravenous IV solution and a course of multi-ingredient dietary supplements on burnout in nurses in the emergency room. FDA determined IND required.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>IRB# 20184140:</th>
<th>IND Needed</th>
</tr>
</thead>
<tbody>
<tr>
<td>Determine if the use of IBGard (peppermint oil) reduces the amount of colon spasms during colonoscopy and whether this improves the rate of polyp detection during colonoscopy. FDA determined IND required.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>IRB# 20205846:</th>
<th>IND Needed</th>
</tr>
</thead>
<tbody>
<tr>
<td>The purpose of this research study is to determine what dosage of N-Acetyl-Cysteine (NAC) can be used safely in patients with ovarian cancer who are receiving a platinum-based chemotherapy. This study is also looking at whether the addition of NAC will lessen or prevent cognitive impairment due to chemotherapy, including memory and thinking skills. FDA determined IND required.</td>
<td></td>
</tr>
</tbody>
</table>

Lawfully Marketed Drugs:
The product must be legally marketed as a drug, meaning it has a New Drug Application (NDA), Abbreviated New Drug Application (ANDA), or Biologics Licensing Application (BLA) that was approved by the FDA. The labeling or package insert details the approved indications for use and dosage and administration. Imported drugs, compounded drugs are not lawfully marketed drugs. Search for FDA Approved Drugs.

Controlled Substances: California law, pursuant to Health & Safety Code Sections §11480 & §11481, requires proposed research studies using certain opioid, stimulant, and hallucinogenic drugs classified as Schedule I and Schedule II Controlled Substances as their main study drug(s), to be reviewed and authorized by the Research Advisory Panel of California in the Attorney General’s Office. This includes human subject research on all parts of the Cannabis sativa K. (marijuana) plant, including derivatives and extracts.1 Read the Guidelines. Read the UC Policy. Search for a Controlled Substance.

---

1 DEA-approved source: Only the University of Mississippi is authorized to produce marijuana plant-based products for use by researchers in the U.S.
Medical Device Assessment Guidance

The following is provided in part from this FDA Guidance, this FDA Guidance and 21 CFR 812. If the device has already been evaluated by the FDA as part of an FDA-approved investigational device exemption (IDE) AND the device will be used as described in the IDE application, STOP HERE. If not, proceed to Step 1 and begin the assessment.

1. **Is the device a medical device?**
   Per 21 U.S.C. 321(h), a medical device is an instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent, or other similar or related article, including any component, part, or accessory, which is:
   a. Recognized in the official National Formulary, or the United States Pharmacopeia, or any supplement to them,
   b. Intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease, in man or other animals, or
   c. Intended to affect the structure or any function of the body of man or other animals, and which does not achieve its primary intended purposes through chemical action within or on the body of man or other animals and which is not dependent upon being metabolized for the achievement of its primary intended purposes.
   
   If 1a, 1b, 1c is TRUE go to 2!

2. **Does this study collect safety and/or effectiveness data for this particular device?**
   a. If safety and/or effectiveness are not studied for a device and that particular device is NOT the object of the investigation, a device risk determination under 21 CFR 812 does not apply.
   
   If 2 is TRUE go to 3! If 2 is NOT TRUE, STOP HERE.

3. **Is the device approved for marketing in the United States and used in accordance with one of the following?**
   A device studied for safety and effectiveness is exempt from the requirement for an IDE if:
   (1) the device is approved by any FDA approval process (a-e below), and 
   (2) the device is investigated in accordance with the indications in the approved labeling.
   a. 510(k) Exempt category (no FDA application needed)
      i. The FDA has exempted almost all Class I devices.
      ii. The FDA has published a list of Class II devices considered 510K exempt.
   b. De Novo Devices (FDA application needed)
      i. The De Novo process provides a pathway to classify novel medical devices for which general controls alone, or general and special controls, provide reasonable assurance of safety and effectiveness for the intended use, but for which there is no legally marketed predicate device. De Novo classification is a risk-based classification process.
      ii. Devices that are classified into class I or class II through a De Novo classification request (De Novo request) may be marketed and used as predicates for future premarket notification [510(k)] submissions.
   c. FDA 510(k) clearance (cleared by FDA)
      i. A 510(k) is a premarket submission made to FDA to demonstrate that the device to be marketed is at least as safe and effective, that is, substantially equivalent, to a legally marketed device (21 CFR 807.92(a)(3)) that is not subject to PMA.
   d. Pre-Market Approval (new FDA approved devices)
      i. PMA is the most stringent type of device marketing application required by FDA. A PMA is an application submitted to FDA to request approval to market. Unlike premarket notification, PMA approval is to be based on a determination by FDA that the PMA contains sufficient valid scientific evidence that provides reasonable assurance that the (Class III) device is safe and effective for its intended use or uses.
   e. Humanitarian Device Exemption (HDE)
      i. Clinical use where there is no evaluation of safety or effectiveness requires IRB review but is not considered research. HUDs evaluated for safety or effectiveness are research.
   f. Marketed Device Product Label/ Brochure

If 3 if TRUE, you can STOP HERE. Do not proceed to the next step.
If the study is using a marketed device off label OR an investigational device with no FDA documentation of an IDE OR otherwise, proceed to 4!
An investigational device exemption (IDE) allows the investigational device to be used in a clinical study in order to collect safety and effectiveness data.

### 4. Is this device exempt from IDE regulations?

- **a.** Investigations that are exempted from 21 CFR 812 are described in Sec. 812.2(c).
- **b.** Investigations may qualify for expedited review.
- **c.** Do not need an IDE application approved by the FDA.

#### 812.2(c) Exempted investigations for these devices

(c) Exempted investigations. This part, with the exception of Sec. 812.119 (disqualification of a clinical investigator), does not apply to investigations of the following categories of devices:

- Devices for veterinary use and used solely for research on animals have been omitted.

#### 812.2(c)(1) A device in commercial distribution before May 28, 1976

(1) A device, other than a transitional device, in commercial distribution immediately before May 28, 1976, when used or investigated in accordance with the indications in labeling in effect at that time. (not used)

#### 812.2(c)(2) Device substantially equivalent to one in distribution before that date

(2) A device, other than a transitional device, introduced into commercial distribution on or after May 28, 1976, that FDA has determined to be substantially equivalent to a device in commercial distribution immediately before May 28, 1976, and that is used or investigated in accordance with the indications in the labeling FDA reviewed under subpart E of part 807 in determining substantial equivalence.

#### 812.2(c)(3) Noninvasive diagnostic device (MOST COMMON EXEMPTION)

(3) A diagnostic device, if the sponsor complies with applicable requirements in Sec. 809.10(c) and if the testing:

- I. Is noninvasive,
- II. Does not require an invasive sampling procedure that presents significant risk,
- III. Does not by design or intention introduce energy into a subject (light and sound = energy), and
- IV. Is not used as a diagnostic procedure without confirmation of the diagnosis by another, medically established diagnostic product or procedure.

Under 21 CFR 812.3(k) **Noninvasive when applied to a diagnostic device or procedure**, means one that does **not** by design or intention:

- A. Penetrate or pierce the skin or mucous membranes of the body, the ocular cavity, or the urethra, or enter the ear beyond the external auditory canal, the nose beyond the nares, the mouth beyond the pharynx, the anal canal beyond the rectum, or the vagina beyond the cervical.
- B. Blood sampling that involves simple venipuncture is considered noninvasive, and the use of surplus samples of body fluids or tissues that are left over from samples taken for non-investigational purposes is also considered noninvasive.

#### 812. (c)(4) Device undergoing consumer preference testing

(4) A device undergoing consumer **preference testing**, testing of a modification, or testing of a combination of two or more devices in commercial distribution if the testing is not for the purpose of determining safety or effectiveness and does not put subjects at risk.

#### 812.2(c)(7) A custom device

(7) A **custom device** as defined in Sec. 812.3(b), unless the device is being used to determine safety or effectiveness for commercial distribution.

If 4 is NOT TRUE, proceed to 5!
5. **Is the proposed use a Significant Risk (SR) device study?**
   a. Full Committee review is always required.
   b. Must follow 21 CFR 812.
   c. Under 21 CFR 812.3(m) a significant risk device means an investigational device that:
      i. *Is intended as an implant and presents a potential for serious risk to the health, safety, or welfare of a subject;*
      ii. *Is purported or represented to be for a use in supporting or sustaining human life and presents a potential for serious risk to the health, safety, or welfare of a subject;*
      iii. *Is for a use of substantial importance in diagnosing, curing, mitigating, or treating disease, or otherwise preventing impairment of human health and presents a potential for serious risk to the health, safety, or welfare of a subject;* or
      iv. *Otherwise presents a potential for serious risk to the health, safety, or welfare of a subject.*
   d. IRBs should make the SR or NSR determination about a study by reviewing relevant information at a convened meeting. This information includes the description of the device, reports of prior investigations conducted with the device, the proposed investigational plan, and subject selection criteria.
   e. SR determination must be based on seriousness of harm that may result from the use of the device in protocol related tests and procedures in addition to the harm that may be caused by the device.
   f. The sponsor should provide the IRB with a risk assessment and the rationale used in making its SR or NSR determination.
   g. The convened IRB can disagree with the sponsor’s determination.
   h. If SR, must have an IDE application approved by FDA before they may proceed.
   i. Researcher may include documentation of SR determination from the FDA, if on file.

If 5 is NOT TRUE, proceed to 6!

6. **Is the proposed use a Non-Significant Risk (NSR) device study?**
   a. Initial Full Committee review required for NSR determination.
   b. A Non-Significant Risk (NSR) device is an investigational device that does not meet the definition of a significant risk device.
   c. If determined NSR, future reviews may be expedited via category 9 if the research involves no more than minimal risk and no additional risk are identified. This must be documented in the minutes at time of initial full committee review.
   d. The sponsor does not need to submit an IDE to FDA before starting the study.
   e. Must follow the abbreviated requirements at 21 CFR 812.2(b) (IRB approval, labeling, AE reporting, records).
   f. Expedited Review: if the FDA has made an NSR determination and the research poses no greater than minimal risk, the study may be submitted for expedited review (per HRP Policy # 42).

If 6 is TRUE, NSR- DONE!
Clinical decision support software (CDS) for healthcare providers and patients that provide clinical decision support may be considered a device subject to 21 CFR 812 unless the following 5 criteria are met:

a. **Intended to provide recommendations to a healthcare provider** and not the patient.
b. **NOT intended** to acquire, process, or analyze a medical image or signal from an in vitro diagnostic device (e.g., HIV tests)
c. **Intended to display or analyze** medical information about a specific patient or other generalized medical information (e.g., peer reviewed clinical studies)
d. **Intended to support or provide recommendations to a health care provider** (HCP) about prevention, diagnosis, or treatment of a disease or condition
e. **Not intended for the HCP to rely primarily on any of the recommendations to make a diagnosis** or treatment decision regarding a patient

**Considerations for Physiological Research:**
- Are the investigators evaluating how well the device works? If so, the IRB should consider that this a medical device.
- Do the investigators understand that the device works, and they are using the device to assess physiology or anatomy? If so, the IRB should consider that this is not a medical device. If not a medical device, IDE regulations do not apply. IRB approval and consent applies

**Real IRB Examples of Non-Medical Devices:**
(Data from these applications were not being used as part of treatment of patient or prevention of disease)
- Fitbit
- My Fitness Pal
IRB Assessment of Risk & Benefit for Research Involving Children (Subpart D)

45 CFR 46.403 (HHS-Subpart D) & 21 CFR 50.50 (FDA-Subpart D) *: The IRB must assure that all applicable criteria of this subpart have been met (refer to and complete the Reviewer’s Supplemental Checklist “D” for Children).

<table>
<thead>
<tr>
<th>Regulatory Category</th>
<th>IRB Requirement</th>
</tr>
</thead>
<tbody>
<tr>
<td>45 CFR 46.404 &amp; 21 CFR 50.51</td>
<td></td>
</tr>
</tbody>
</table>
No more than Minimal Risk (Expedited level research only)  
- Confirm provisions for child assent  
- Confirm provisions for parental consent – If consent is required, determine whether it is acceptable for only one parent or guardian to sign the consent. |
| 45 CFR 46.405 & 21 CFR 50.52 |  
Greater than Minimal Risk: Direct benefit to subjects  
- Determine that risk is justified by anticipated benefit  
- Benefit/risk relationship is at least as favorable as alternative approaches  
- Determine whether it is acceptable for only one parent or guardian to sign the consent. |
| 45 CFR 46.406 & 21 CFR 50.53 |  
Greater than Minimal Risk: No direct benefit to subjects, but likely to yield generalizable knowledge about the subject’s disorder or condition  
- Determine there is only a minor increase over minimal risk  
- Determine intervention presents experiences relatively commensurate with alternative medical, dental, psychological or educational interventions  
- Determine the procedure is likely to yield knowledge of vital importance to understanding or ameliorating the subject’s disorder  
- Confirm adequate provisions for child’s assent and parental permission  
- Permission of both parents is required |
| 45 CFR 46.407 & 21 CFR 50.54 |  
Not otherwise approved in categories above  
- Determine the research provides a reasonable opportunity to further the understanding, prevention, or alleviation of a serious problem  
- If DHHS funded refer for review by HHS secretary after consultation with a panel of experts  
- If non-DHHS funded not approvable by the IRB.  
- If FDA applies study must be submitted to the Commissioner of Food and Drugs for approval  
- Permission of both parents is required |

* Children who are wards of the state or any other agency, institution, or entity can be included in research approved under 45 CFR 46.405 & 21 CFR 50.52 and 45 CFR 46.406 & 21 CFR 50.53 only if such research is: (1) Related to their status as wards; or (2) Conducted in schools, camps, hospitals, institutions, or similar settings in which the majority of children involved as subjects are not wards. If the research is approved, the IRB must require appointment of an advocate for each child who is a ward, in addition to any other individual acting on behalf of the child as guardian or in loco parentis.

IRB Determinations – Children  
Revised October 2016
**IRB Assessment of Risk & Benefit for Research Involving Pregnant Women and Fetuses (Subpart B)**

**45 CFR 46.203 (HHS – Subpart B):** The IRB must assure that all applicable criteria for this subpart have been met. The IRB must refer to and complete the Reviewer’s Supplemental Checklist “B” for Pregnant Women, Fetuses and Neonates. *Note: When neonates of uncertain viability and nonviable neonates are involved in research, 45 CFR 46.205 must be addressed.*

The IRB must decide which one of the regulatory categories listed below best represents the proposed research:

<table>
<thead>
<tr>
<th>Risk is no more than minimal</th>
<th>Benefit to mother only</th>
<th>Benefit to mother and fetus</th>
<th>Benefit to fetus only</th>
<th>No direct benefit or benefit to society only</th>
</tr>
</thead>
<tbody>
<tr>
<td>45 CFR 46.204 (d)</td>
<td>Mother's consent only</td>
<td>Mother's consent only</td>
<td>45 CFR 46.204 (e)</td>
<td>45 CFR 46.204 (d)</td>
</tr>
<tr>
<td>Risk is greater than minimal</td>
<td>45 CFR 46.204 (d)</td>
<td>45 CFR 46.204 (d)</td>
<td>45 CFR 46.204 (e)</td>
<td>45 CFR 46.204 (d)</td>
</tr>
<tr>
<td>Mother's consent only</td>
<td>Mother's consent only</td>
<td>Mother's consent only</td>
<td>Mother and father's consent</td>
<td>Not approvable unless*</td>
</tr>
</tbody>
</table>

* The risk to the fetus is not greater than minimal and the purpose of the research is the development of important biomedical knowledge which cannot be obtained by any other means. Only Mother’s consent is required. **NOTE:** For DoD supported research, there are exceptions (e.g., the phrase “biomedical knowledge” in subpart B shall be replaced with “generalizable knowledge” throughout the subpart). Refer to DoDI 3216.02, version November 8, 2011.

IRB Determinations – Pregnant Women, Fetuses and Neonates
Revised October 2016
IRB Determinations

IRB Assessment of Risk & Benefit for Research Involving Prisoners (Subpart C)

IRB Responsibilities:

1. Review the completed Appendix C when considering the following.
2. The IRB must assure that all of the seven criteria have been met per 45 CFR 46.305(a)(1-7). See Table 1.
   a) The IRB may consider if research qualifies for epidemiologic research where prisoners are not a particular focus of the research [FR Doc. 03-15580 6-19-03].

Table 1. Federal Requirements for Prisoner Research

<table>
<thead>
<tr>
<th>Requirement</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>The research under review represents one of the four following categories of research permissible under 45 CFR 46.306(a)(2) which are as follows:</td>
<td>45 CFR 46.305 (a)(1)</td>
</tr>
<tr>
<td>i. Study of the possible causes, effects, and processes of incarceration, and of criminal behavior, provided that the study presents no more than minimal risk and no more than inconvenience to the subjects;</td>
<td></td>
</tr>
<tr>
<td>ii. Study of prisons as institutional structures or of prisoners as incarcerated persons, provided that the study presents no more than minimal risk and no more than inconvenience to the subjects;</td>
<td></td>
</tr>
<tr>
<td>iii. Research on conditions particularly affecting prisoners as a class (for example, vaccine trials and other research on hepatitis which is much more prevalent in prisons than elsewhere; and research on social and psychological problems such as alcoholism, drug addiction and sexual assaults) provided that the study may proceed only after the Secretary has consulted with appropriate experts including experts in penology medicine and ethics, and published notice, in the FEDERAL REGISTER, of his intent to approve such research; or</td>
<td></td>
</tr>
<tr>
<td>iv. Research on practices, both innovative and accepted, which have the intent and reasonable probability of improving the health or well-being of the subject. In cases in which those studies require the assignment of prisoners in a manner consistent with protocols approved by the IRB to control groups which may not benefit from the research, the study may proceed only after the Secretary has consulted with appropriate experts, including experts in penology medicine and ethics, and published notice, in the FEDERAL REGISTER, of his intent to approve such research.</td>
<td></td>
</tr>
<tr>
<td>Any possible advantages accruing to the prisoner through his or her participation in the research, when compared to the general living conditions, medical care, quality of food, amenities and opportunity for earnings in the prison, are not of such a magnitude that his or her ability to weigh the risks of the research against the value of such advantages in the limited choice environment of the prison is impaired;</td>
<td>45 CFR 46.305 (a)(2)</td>
</tr>
<tr>
<td>The risks involved in the research are commensurate with risks that would be accepted by non prisoner volunteers;</td>
<td>45 CFR 46.305 (a)(3)</td>
</tr>
<tr>
<td>Procedures for the selection of subjects within the prison are fair to all prisoners and immune from arbitrary intervention by prison authorities or prisoners. Unless the principal investigator provides to the Board justification in writing for following some other procedures, control subjects must be selected randomly from the group of available prisoners who meet the characteristics needed for that particular research project;</td>
<td>45 CFR 46.305 (a)(4)</td>
</tr>
<tr>
<td>The information is presented in language which is understandable to the subject population;</td>
<td>45 CFR 46.305 (a)(5)</td>
</tr>
<tr>
<td>Adequate assurance exists that parole boards will not take into account a prisoner's participation in the research in making decisions regarding parole, and each prisoner is clearly informed in advance that participation in the research will have no effect on his or her parole; and</td>
<td>45 CFR 46.305 (a)(6)</td>
</tr>
<tr>
<td>Where the Board finds there may be a need for follow-up examination or care of participants after the end of their participation, adequate provision has been made for such examination or care, taking into account the varying lengths of individual prisoners' sentences, and for informing participants of this fact.</td>
<td>45 CFR 46.305 (a)(7)</td>
</tr>
</tbody>
</table>
IRB Member Conflict of Interest Disclosure

It is the expectation of the University that IRB members will voluntarily recuse themselves from review and discussion of research protocols by leaving the room if they have a conflict of interest. Members of the IRB must disclose to the IRB Chair or Administrator if a conflict of interest exists in the review of research or compliance matters for the IRB.

1. **Affiliation with research**: Members who are an investigator or faculty sponsor on the project under review, or whose spouse or child is an investigator or faculty sponsor, must recuse themselves from IRB action.

2. **Compromised Objectivity**: Members who believe existing circumstances may directly affect their objectivity should request that they be recused from IRB action. For example:
   a. A member is involved in a potentially competing research program
   b. A member has access to funding or intellectual information that may create an unfair competitive advantage
   c. A member’s personal biases may interfere with his or her impartial judgment

3. **Financial Interests**: Members who have any disclosable financial interests (i) that would reasonably appear to be affected by the research; or (ii) in entities whose financial interests would reasonably appear to be affected by the research must recuse themselves from IRB action.

   **Disclosable Financial Interests are anything of monetary value for an investigator, their spouse and dependent children, including:**
   - Ownership interest, stock, stock options, or other financial interest related to the research, unless it meets all four tests:
     - Less than $10,000 when aggregated for the immediate family and
     - Publicly traded on a stock exchange and
     - Value will not be affected by the outcome of the research and
     - Less than 5% interest in any one single entity.
   - Compensation related to the research, including salary, consultant payments, honoraria, royalty payments, dividends, loans, or any other payments or consideration with value, including payments made to the University Health Sciences Compensation Plan, unless it meets both of the following tests:
     - Less than $10,000 in the past year when aggregated for the immediate family and the
     - Amount will not be affected by the outcome of the research.
   - Proprietary interest related to the research including, but not limited to, a patent, trademark, copyright or licensing agreement.
   - Board or executive relationship (e.g., director, officer, partner, or trustee) related to the research, regardless of compensation.
An Algorithm for IRB Evaluation of Studies That Involve Placebo

Is placebo being used in place of standard therapy?

- **YES**
  - Is standard treatment considered to be effective?
    - **YES**
      - The risk of placebo is high. Additional protections are required that recognize the fact that informed consent is often suboptimal. An important consideration is a study design that minimizes risk.
    - **NO**
      - Consider alternate study designs: Is it possible to predict the placebo response rate in this study with a reasonable degree of accuracy?
        - **NO**
          - Evaluate the credibility of altruism: Could this trial benefit future patients to the point that a reasonable person with an average degree of altruism and risk-aversiveness would consent to being randomized in this trial?
            - **NO**
              - A study with concomitant placebo control is not ethical. Alternative study designs are likely to produce meaningful results with less risk to subjects.
            - **YES**
              - The use of placebo is ethical.
        - **YES**
          - The use of placebo is ethical.
      - The risk of placebo is minor, temporary discomfort. Standard informed consent procedures are adequate. The use of placebo is ethical.

- **NO**
  - Could the use of placebo instead of standard treatment cause irreversible health problems or extreme suffering?
    - **YES**
      - The use of placebo is ethical.
    - **NO**
      - A study with concomitant placebo control is not ethical.
### Ancillary Partner Impact Review Process

#### How Does This Ancillary Partner Impact Research?
- **Cannabis Research Review Committee (CRR)**
  Ms. Grace Park
  parkgj@uci.edu
  Securing CRRC review for the use of cannabis in research is the responsibility of the LR. CRRC is recommended before clinical research procedures are initiated. CRRC review will assess the feasibility of study conduct and help to ensure compliance related to research involving cannabis.

- **Center for Clinical Research (CCR)**
  UCI Clinical Trials
  UCIClinicalTrials@hs.uci.edu
  In addition to serving those Department that fall under the umbrella of CCR (School of Medicine), CCR review may be utilized by non-CCR, Non CFCCC, Non Alpha Stem Cell Researchers to initiate the requisite Qualified Clinical Trial (QCT) determination and subsequent Coverage Analysis (CA).
  - QCT is needed for clinical trials using UCI Health items and services, as this will direct the requirement of completing a Coverage Analysis (CA) if a study is deemed qualified.
  - Coverage Analysis is required as Medicare and most third-party payers cover the routine costs of qualifying clinical trials as well as reasonable and necessary items and services used to diagnose and treat complications arising from participation in all clinical trials.

- **Chao Family Comprehensive Cancer Center (CFCCC) Protocol Review and Monitoring Committee (PRMC)**
  Cancer Center: CancerCenter_Committees@hs.ucri.edu
  Cancer Center review is required (with documentation of clearance) if the following criteria is met:
  - The research is cancer-related* and hypothesis-driven.
  - The research involves interaction with participants, including obtaining consent.
  - Note the following submission timing requirements:
    - Investigator-initiated studies that are greater than minimal risk require Cancer Center approval prior to IRB submission.
    - NCI National Clinical Trial Network, industry-sponsored studies, and minimal risk studies may be submitted to the Cancer Center and the IRB concurrently.
    - Studies involving participants with cancer, any active intervention (e.g., behavioral or pharmacological) involving cancer or pre-cancerous participants, or participants of a study involving a specific cancer focus (e.g., program evaluations, quality-of-life survey health education, etc.).

- **Clinical Engineering (CE)**
  714-456-3686
  UCI Clinical Engineering must approve the use of medical equipment in an area that operates under the hospital's license and/or equipment used on the hospital's patients and research subjects. Securing CE approval is the responsibility of the LR and is required before clinical research procedures can be initiated.

- **Conflict of Interest Oversight Committee (COIOC)**
  Ms. Nadia Wong
  nadlaw@uci.edu
  COIOC review is required for new, renewals and amendments when researcher/s report a disclosable financial conflict of interest. Documentation of COIOC review, including the COIOC proposed management plan and consent language (as applicable) must be provided to the IRB / IRB Chair for final review and approval.

- **Dual Use Research Committee (DURC)**
  Ms. Grace Park
  parkgj@uci.edu
  Securing DURC review is the responsibility of the LR and is recommended before clinical research procedures are initiated.

- **Environmental Health and Safety (EHS)**
  ecchlit@uci.edu
  When using a controlled substance on the Irvine campus, securing EHS review for the security of the substance is the responsibility of the LR and is recommended before clinical research procedures are initiated.
  Note: For smoking or tobacco use in research, researchers should check in with the EHS Smoke and Tobacco Free Policy Task Force to confirm the research is appropriate.

#### When Does IRB Review Occur?
- Upon IRB approval of the protocol.
- Upon IRB approval of the protocol.
- Upon IRB approval of the protocol.
- Upon IRB approval of the protocol.

#### When Are IRB-Approved Documents Released?
- Upon IRB approval of the protocol.
- Upon IRB approval of the protocol.
- Upon IRB approval of the protocol.
- Upon IRB approval of the protocol.

---

**REFERENCE:** ANCILLARY PARTNER IMPACTS ON UCI IRB REVIEW + APPROVAL

Please note as a courtesy HRP Staff may notify the Lead Researcher (LR) / the Research Team if an ancillary partner may apply to the research.
### Ancillary Partner

<table>
<thead>
<tr>
<th><strong>Epidemiology and Infection Prevention (EIP)</strong>&lt;br&gt;Health Epidemiology and Infection Prevention Program: 714-456-5221</th>
<th>Securing EIP Committee approval is the responsibility of the LR and is required before clinical research procedures can be initiated. EIP looks to identify research protocols involving humans that need further review by EIP for clearance due to trial of devices or biologic or infectious agents (e.g., live vaccine, probiotic) at UC Irvine Healthcare.</th>
<th>Concurrent with EIP</th>
<th>Upon IRB approval of the protocol.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Export Control Review Process (EXP CTRL)</strong>&lt;br&gt;<a href="mailto:exportcontrol@uci.edu">exportcontrol@uci.edu</a></td>
<td>Securing EXP CTRL review is the responsibility of the LR. EXP CTRL review is recommended as part of considering the feasibility of study conduct and prior to research initiated in countries subject to Office of Foreign Assets Control (OFAC) sanctions. If more than a general license is needed, IRB approval will be held pending receipt of license (“M”).</td>
<td>Concurrent with EXP CTRL except when research meets criteria in red</td>
<td>Upon IRB approval of the protocol.</td>
</tr>
</tbody>
</table>
| **Human Stem Cell Research Oversight Committee (hSCRO)**<br>Contact: hSCRO@uci.edu | hCRO is required when:  
- There is use or procurement of the following human materials: gametes, embryos, adult pluripotent cells, fetal tissue, fetal stem cells, or embryonic stem cells.  
- Generation of new lines of human pluripotent stem cells from whatever source and by whatever means (e.g., obtaining human embryos / gametes under a UCI IRB approved protocol to create human embryonic stem cell (HESC) lines, obtaining skin tissue under a UCI IRB approved protocol to create induced pluripotent stem cell (iPSC) lines.  
- Transplantation of neural stem cells into humans | Concurrent with hSCRO | When the source of materials to derive induced pluripotent stem cells (iPSC’s) originate from a UCI IRB protocol, the IRB review precedes hSCRO Full Committee review. A hSCRO subcommittee will confirm provenance specific language in the consent form, prior to IRB review and/or approval. When hSCRO review is applicable to an IRB submission, and the source of materials to derive induced pluripotent stem cells (iPSC’s) does not originate from the UCI IRB protocol, IRB and hSCRO Full Committee review and approval may occur independently. |
| **Institutional Biosafety Committee (IBC)**<br>Ms. Alice Lee: 949-624-8024, ibc@uci.edu | Any research involving the deliberate transfer of recombinant and synthetic nucleic acids, materials or microorganisms modified using recombinant and synthetic nucleic acids into one or more human research participants must be approved by the UCI IBC. Securing IBC approval for biosafety issues (e.g., blood draws, specimens transferred from clinic to UCI lab, etc.) is the responsibility of the LR and is required before clinical research procedures are initiated. Note: The UC-Irvine Human Gene Transfer Institutional Biosafety Committee (HGT IBC) is being administered by Clinical Biosafety Services (CBS). Researchers should still submit through the UCI IBC, who will coordinate the CBS process. | Concurrent with IBC | The IRB may grant conditional approval (i.e., “M”) of the protocol pending IBC clearance. The IRB Chair / VC can review the IBC determination. If additional risks or significant consent form revisions are required/suggested, or the IRB Chair / VC have concerns, full board IRB re-review is required. Upon the IRB’s acceptance of the IBC approval and the IRB documentation includes the required statements, IRB approval may be released. |
| **Investigational Drug Service (IDS)**<br>Dr. Zahra Azadbadi, IDS Supervisor 714-456-7833, zazadbad@uci.edu | The IDS is a division of the Pharmacy Department that must be consulted in advance of study initiation concerning the storage, handling, and dispensing of investigational drugs, agents, and biologics to assure compliance with all IDS policies and procedures, Institutional, State, Federal (FDA) and Joint Commission on Accreditation of Hospital Organizations (JCAHO) requirements. The HRP staff sends the IDS a report bi-monthly to provide an update on the status of pending new and renewals involving clinical investigations. **Note the following submission timing requirements:**  
- Securing IDS review or consult is the responsibility of the LR and is recommended before clinical research procedures are initiated.  
- If an Investigator Initiated Trial (IIT), evidence of IDS clearance is required in order to release IRB approval. In order to best facilitate this in Kuail Research Protocols (“M”). | Concurrent with IDS except when research meets criteria in red | The IRB may grant conditional approval (i.e., “M”) of the protocol pending IDS clearance. The IRB Chair / VC can review the IDS determination. If additional risks or significant consent form revisions are required/suggested, or the IRB Chair / VC have concerns, full board IRB re-review is required. Upon the IRB’s acceptance of the IDS approval and the IRB documentation includes the required statements, IRB approval may be released. |
| **Laser Safety Committee (LSC)**<br>For more info visit: http://www.ehs.uci.edu/radsafe.html | Securing LSC review or consult is the responsibility of the LR and is recommended before clinical research procedures are initiated. | Concurrent with LSC | Upon IRB approval of the protocol. |

**REFERENCE:** ANCILLARY PARTNER IMPACTS ON UCI IRB REVIEW + APPROVAL

**Please note as a courtesy HRP Staff may notify the Lead Researcher (LR) / the Research Team if an ancillary partner may apply to the research.**

**Institutional Review Board**

**Page 2 of 3**
## ANCILLARY PARTNER IMPACTS ON UCI IRB REVIEW + APPROVAL

**REFERENCE:**

Please note as a courtesy HRP Staff may notify the Lead Researcher (LR) / the Research Team if an ancillary partner may apply to the research.

<table>
<thead>
<tr>
<th>Ancillary Partner</th>
<th>How Does This Ancillary Partner Impact Research?</th>
<th>When Does IRB Review Occur?</th>
<th>When Are IRB-Approved Documents Released?</th>
</tr>
</thead>
<tbody>
<tr>
<td>OR/Procedural Services Committee</td>
<td>Notifying the OR/Procedural Services Committee is the responsibility of the LR and is required before clinical research procedures can be initiated in the surgical units.</td>
<td>Concurrent with OR/Procedural Services</td>
<td>Upon IRB approval of the protocol.</td>
</tr>
<tr>
<td>Pathology Clearance (PATH)</td>
<td>Per HRP Policy 15 and the UCIMC Anatomical Pathology/Surgical Pathology - Procedure Number: S-23, all specimens removed from clinic or the operating room must be sent to UCI Health Pathology for review and documentation by a pathologist.</td>
<td>Concurrent with PATH</td>
<td>Upon IRB approval of the protocol.</td>
</tr>
<tr>
<td>Radiation Safety Committee (RSC)</td>
<td>All protocols involving radiation exposure to normal subjects and/or clinical human subjects when the exposure is not considered standard-of-care must be referred to the RSC. (Use the flowchart on Page 5 of the Application for Human Subject Research Involving Radiation @ <a href="https://www.ehs.uci.edu/programs/radiation/RSCReviewAppGuide.doc">https://www.ehs.uci.edu/programs/radiation/RSCReviewAppGuide.doc</a> to determine level of RSC review.)</td>
<td>Concurrent with RSC</td>
<td>If protocol requires RSC subcommittee review, approval documents will be released upon IRB approval. The IRB may grant conditional approval (i.e., “M”) of the protocol pending RSC full board review/approval. The IRB Chair/VC can review the RSC determination. If additional risks or significant consent form revisions are required/suggested, or the IRB Chair/VC have concerns, full board IRB re-review is required.</td>
</tr>
<tr>
<td>Radioactive Drug Research Committee (RDRC) Contact HRP Staff</td>
<td>When the research involves radioactive materials, documentation of RDRC review, including RDRC comments and approval is required before the IRB can grant approval. Alternatively, documentation of an IND from the FDA is required before final IRB approval. Sufficient documentation of an IND includes IND letter from FDA or IND number on Sponsor’s Master Protocol, if externally sponsored.</td>
<td>N/A</td>
<td>Committee currently inactive</td>
</tr>
<tr>
<td>Research Revenue Integrity (RRI) <a href="mailto:ResearchRevenueIntegrity@hs.uci.edu">ResearchRevenueIntegrity@hs.uci.edu</a></td>
<td>RRI performs a sign-off on behalf of UC Irvine Health (study activation requirement), including review and approval of all coverage analysis. RRI is responsible for ensuring all technical and professional services provided under a clinical research study at any UC Irvine Health location are identified, coded, recharged and/or billed correctly. RRI maintains research rates and the research charge master.</td>
<td>Concurrent with RRI</td>
<td>Upon IRB approval of the protocol.</td>
</tr>
<tr>
<td>Scientific Review (Statistical Methods) (SR) Contact HRP Staff</td>
<td>Scientific review clearance for investigator-initiated full committee protocols is required before IRB review may proceed. Reviewer comments, including scientific review clearance must be provided to the IRB at the time of their review. Exempt and Expedited level protocols DO NOT require scientific review unless mandated by the IRB Subcommittee. The IRB Chair or VC may require SR review for significant study amendments. Patient care that does not qualify as “research” yet regulations require prospective IRB review and approval (e.g., expanded access, HUD) DO NOT require scientific review.</td>
<td>Initial hold IRB review for SR. If minor SR comments proceed with IRB review and include SR comments in memo to LR. If significant comments, LR must respond to memo and SR re-review prior to IRB review.</td>
<td>Upon IRB approval of the protocol.</td>
</tr>
</tbody>
</table>
### Meeting Calendar 2024

**January**

- S: Sunday
- M: Monday
- T: Tuesday
- W: Wednesday
- T: Thursday
- F: Friday
- S: Saturday

**February**

**March**

**April**

**May**

**June**

**July**

**August**

**September**

**October**

**November**

**December**

**Holiday**

**IRB A Meeting Date**

**IRB A Deadline Date**

**IRB B Meeting Date**

**IRB B Deadline Date**

**IRB C Meeting Date**

**IRB C Deadline Date**

**IRB A & C Meeting Date**

**IRB B & C Meeting Date**

**IRB A & C Deadline Date**
Researchers: Exempt Self-Determination may be done under specific exempt categories and with specific subject populations. Visit the Levels of Review webpage to learn more about what categories can be confirmed by the Lead Researcher, and those that require UCI IRB review.

1. Research, conducted in established or commonly accepted educational settings that specifically involves normal educational practices that are not likely to adversely impact students’ opportunity to learn required educational content or the assessment of educators who provide instruction. This includes most research on regular and special education instructional strategies, and research on the effectiveness of or the comparison among instructional techniques, curricula, or classroom management methods.

2. Research that includes only interactions involving educational tests (cognitive, diagnostic, aptitude, achievement), survey procedures, interview procedures, or observation of public behavior (including visual or auditory recording) if at least one of the following criteria are met:

   i. The information obtained is recorded by the investigator in such a manner that the identity of the human subjects cannot readily be ascertained, directly or through identifiers linked to the subjects;

   ii. Any disclosure of the human subjects' responses outside the research would not reasonably place the subjects at risk of criminal or civil liability or be damaging to the subjects' financial standing, employability, educational advancement, or reputation; OR

   iii. The information obtained is recorded by the investigator in such a manner that the identity of human subjects can readily be ascertained, directly or through identifiers linked to the subjects, and an IRB conducts a limited review to make the determination required by 45 CFR 46.111(a)(7)

   Note: For Category 2iii, any disclosure of the human subjects' responses outside the research would reasonably place the subjects at risk of criminal or civil liability or be damaging to the subjects' financial standing, employability, educational advancement, or reputation.

3i. Research involving benign behavioral interventions in conjunction with the collection of information from an adult subject through verbal or written responses (including data entry) or audiovisual recording if the subject prospectively agrees to the intervention and information collection and at least one of the following criteria is met:

   A. The information obtained is recorded by the investigator in such a manner that the identity of the human subjects cannot readily be ascertained directly or through identifiers linked to the subjects;

   B. Any disclosure of the subjects’ responses outside the research would not reasonably place the subjects at risk of criminal or civil liability or be damaging to the subjects’ financial standing, employability, educational advancement, or reputation; OR

   C. The information obtained is recorded by the investigator in such a manner that the identity of the human subjects can readily be ascertained, directly or through identifiers linked to the subject, and an IRB conducts a limited IRB review to make the determination required by 45 CFR 46.111(a)(7)

---

1 Research funded/supported by the Department of Justice is not currently eligible for the 2018 Exempt Categories.
2 Children may be included if procedures include educational tests or observation of public behavior only and the researcher does not participate in the activities being observed.
Note: For Category 3iC, any disclosure of the human subjects' responses outside the research would reasonably place the subjects at risk of criminal or civil liability or be damaging to the subjects' financial standing, employability, educational advancement, or reputation.

ii. For the purpose of this provision, benign behavioral interventions are brief in duration, harmless, painless, not physically invasive, not likely to have a significant adverse lasting impact on the subjects, and the investigator has no reason to think the subjects will find the interventions offensive or embarrassing. Provided all such criteria are met, examples of such benign behavioral interventions would include having the subjects play an online game, having them solve puzzles under various noise conditions, or having them decide how to allocate a nominal amount of received cash between themselves and someone else.

iii. If the research involves deceiving the subjects regarding the nature or purposes of the research, this exemption is not applicable unless the subject authorizes the deception through a prospective agreement to participate in research in circumstances in which the subject is informed that he or she will be unaware of or misled regarding the nature or purposes of the research.

4. Secondary research for which consent is not required: Secondary research uses of identifiable private information or identifiable biospecimens, if at least one of the following criteria is met:

i. The identifiable private information or identifiable biospecimens are publicly available;

Note: Category 4i applies to secondary research use of archives in a public library, for example, or to government or other institutional records where public access is provided on request, or from a commercial entity if the information is provided to members of the public on request or if the only requirement for obtaining the information is paying a user fee, registering or signing in as a visitor to an archive. It would also apply if a commercial entity made identifiable biospecimens publicly available to anyone on request or for a fee.

ii. Information, which may include information about the biospecimens, is recorded by the investigator in such a manner that the identity of human subjects cannot readily be ascertained directly or through identifiers linked to the subjects, the investigator does not contact the subjects, and the investigator will not re-identify subjects;

iii. Note: Based on recent UC Office of the President guidance, due to HIPAA considerations, 4iii will no longer be used at UCI. Consider Exempt Category 4ii or Expedited 5 instead.

iv. The research is conducted by, or on behalf of, a Federal department or agency using government-generated or government-collected information obtained for nonresearch activities, if the research generates identifiable private information that is or will be maintained on information technology that is subject to and in compliance with section 208(b) of the E-Government Act of 2002, 44 U.S.C. 3501 note, if all of the identifiable private information collected, used, or generated as part of the activity will be maintained in systems of records subject to the Privacy Act of 1974, 5 U.S.C. 552a, and, if applicable, the information used in the research was collected subject to the Paperwork Reduction Act of 1995, 44 U.S.C. 3501 et seq.

5. Research and demonstration projects that are conducted or supported by a Federal department or agency, or otherwise subject to the approval of department or agency heads (or the approval of the heads of bureaus or other subordinate agencies that have been delegated authority to conduct the research and demonstration projects), and that are designed to study, evaluate, improve, or otherwise examine public benefit or service programs, including procedures for obtaining benefits or services under those programs, possible changes in or alternatives to those programs or procedures, or possible changes in methods or levels of payment for benefits or services under those programs.

6. Taste and food quality evaluation and consumer acceptance studies:

i. If wholesome foods without additives are consumed; OR

ii. If a food is consumed that contains a food ingredient at or below the level and for a use found to be
safe, or agricultural chemical or environmental contaminant at or below the level found to be safe, by
the Food and Drug Administration or approved by the Environmental Protection Agency or the Food
Safety and Inspection Service of the U. S. Department of Agriculture.

7. Storage or maintenance for secondary research for which broad consent is required: Storage or
maintenance of identifiable private information or identifiable biospecimens for potential secondary
research use if an IRB conducts a limited IRB review and makes the determinations required by 45 CRF
46.111(a)(8).

Note: UCI will not adopt the option for broad consent provided in Category 7. UCI’s interpretation of Broad
consent is that it is a system-wide program that allows institutions to track via a central system biospecimens
and data for which individuals provide their broad consent, or decline, as well as the terms of the broad
consent to determine which future research uses remain within scope. This interpretation aligns with the
Health and Human Services (HHS) Secretary’s Advisory Committee on Human Research Protections (SACHRP)
interpretation. Consequently, UCI is taking the same position as all UC’s, Children’s Hospital Orange County,
Harvard, and Johns Hopkins and is not implementing Category 7, because UCI currently lacks a system-wide
program for collecting broad consent.

8. Secondary research for which broad consent is required: Research involving the use of identifiable
private information or identifiable biospecimens for secondary research use, if the following criteria
are met:

i. Broad consent for the storage, maintenance, and secondary research use of the identifiable private
information or identifiable biospecimens was obtained in accordance with 45 CFR 46.116(a)(1)
through (4), (a)(6), and (d);

ii. Documentation of informed consent or waiver of documentation of consent was obtained in
accordance with 45 CFR 46.117;

iii. An IRB conducts a limited IRB review and makes the determination required by 45 CFR
46.111(a)(7) and makes the determination that the research to be conducted is within the scope of
the broad consent referenced in paragraph (d)(8)(i) of this section; and

iv. The investigator does not include returning individual research results to subjects as part of the
study plan. This provision does not prevent an investigator from abiding by any legal requirements to
return individual results.

Note: UCI will consider Category 8 on a case by case basis. Researchers interested in Category 8 should
contact HRP Staff for more information OR consider Expedited Review under Category 5.
1. Clinical studies of drugs and medical devices only when condition (a) or (b) is met.
   a. Research on drugs for which an investigational new drug application (21 CFR Part 312) is not required. (Note: Research on marketed drugs that significantly increases the risks or decreases the acceptability of the risks associated with the use of the product is not eligible for expedited review.)
   b. Research on medical devices for which (i) an investigational device exemption application (21 CFR Part 812) is not required; or (ii) the medical device is cleared/approved for marketing and the medical device is being used in accordance with its cleared/approved labeling.

2. Collection of blood samples by finger stick, heel stick, ear stick, or venipuncture as follows:
   a. from healthy, non-pregnant adults who weigh at least 110 pounds. For these subjects, the amounts drawn may not exceed 550 ml in an 8 week period and collection may not occur more frequently than 2 times per week; or
   b. from other adults and children, considering the age, weight, and health of the subjects, the collection procedure, the amount of blood to be collected, and the frequency with which it will be collected. For these subjects, the amount drawn may not exceed the lesser of 50 ml or 3 ml per kg in an 8 week period and collection may not occur more frequently than 2 times per week.

3. Prospective collection of biological specimens for research purposes by noninvasive means.
   Examples:
   - hair and nail clippings in a non-disfiguring manner;
   - deciduous teeth at time of exfoliation or if routine patient care indicates a need for extraction;
   - permanent teeth if routine patient care indicates a need for extraction;
   - excreta and external secretions (including sweat);
   - uncannulated saliva collected either in an unstimulated fashion or stimulated by chewing gumbase or wax or by applying a dilute citric solution to the tongue;
   - placenta removed at delivery;
   - amniotic fluid obtained at the time of rupture of the membrane prior to or during labor;
   - supra- and subgingival dental plaque and calculus, provided the collection procedure is not more invasive than routine prophylactic scaling of the teeth and the process is accomplished in accordance with accepted prophylactic techniques;
   - mucosal and skin cells collected by buccal scraping or swab, skin swab, or mouth washings;
   - sputum collected after saline mist nebulization.

4. Collection of data through noninvasive procedures (not involving general anesthesia or sedation) routinely employed in clinical practice, excluding procedures involving x-rays or microwaves. Where medical devices are employed, they must be cleared/approved for marketing. (Studies intended to evaluate the safety and effectiveness of the medical device are not generally eligible for expedited review, including studies of cleared medical devices for new indications.)

   Examples: (see next page)
• physical sensors that are applied either to the surface of the body or at a distance and do not involve input of significant amounts of energy into the subject or an invasion of the subject’s privacy;
• weighing or testing sensory acuity;
• magnetic resonance imaging;
• electrocardiography, electroencephalography, thermography, detection of naturally occurring radioactivity, electoretinography, ultrasound, diagnostic infrared imaging, doppler blood flow, and echocardiography;
• moderate exercise, muscular strength testing, body composition assessment, and flexibility testing where appropriate given the age, weight, and health of the individual.

5. Research involving materials (data, documents, records, or specimens) that:
   a. have previously been collected (retrospective) for nonresearch purposes
   b. have previously been collected (retrospective) for research purposes, provided the materials were not collected for the currently proposed research
   c. will be collected (prospective) solely for nonresearch purposes

   (NOTE: Some research in this category may be exempt from the HHS regulations for the protection of human subjects. 45 CFR 46.101(b)(4). This listing refers only to research that is not exempt.)

6. Collection of data from voice, video, digital, or image recordings made for research purposes.

7. Research on individual or group characteristics or behavior (including, but not limited to, research on perception, cognition, motivation, identity, language, communication, cultural beliefs or practices, and social behavior) or research employing survey, interview, oral history, focus group, program evaluation, human factors evaluation, or quality assurance methodologies.

   (NOTE: Some research in this category may be exempt from the HHS regulations for the protection of human subjects. 45 CFR 46.101(b)(2) and (b)(3). This listing refers only to research that is not exempt.)

8. Continuing review of research previously approved by the convened IRB as follows:
   a. where
      • the research is permanently closed to the enrollment of new subjects;
      • all subjects have completed all research-related interventions; and
      • the research remains active only for long-term follow-up of subjects; or
   b. where no subjects have been enrolled and no additional risks have been identified; or
   c. where the remaining research activities are limited to data analysis.

9. Continuing review of research, not conducted under an investigational new drug application or investigational device exemption where categories two (2) through eight (8) do not apply but the IRB has determined and documented at a convened meeting that the research involves no greater than minimal risk and no additional risks have been identified.

1 2007 Federal Register
13. UCI Expanded Category of Minimal Risk Research Procedures: Skin Punch Biopsy for Children and Adults

a. The following limitations apply to the use of this expanded expedited category:
   i. The research is not federally funded and not subject to FDA regulations.
   ii. The biopsy must be no greater than 2 mm.
   iii. A biopsy greater than 2 mm requires full committee review.
   iv. If multiple 2 mm skin punch biopsies are proposed, the IRB will consider whether the procedures in totality rise to a level greater than minimal risk on a case by case basis.
   v. Placement of biopsy must be on the upper inner arm, upper inner thigh, or lower back/upper buttock below the pant line. The location must be agreed upon by the parent or legally authorized representative, the child subject or adult subject, in consultation with the lead researcher.
   vi. Additional considerations for children:
       1. If the child is not affected by the condition under study, s/he must be age 7 or above to allow for assent. Parental permission is required.
       2. If the child is affected by the condition under study, there is no age restriction. Parental permission is required.

b. Additional guidance for researchers (the following text may be included in the IRB submission when describing the procedure):
   i. Use of EMLA or similar topical numbing cream should be used at least 2 hours in advance of the procedure for minors. Then, after selecting a biopsy site on the upper inner arm, upper inner thigh, or lower back/upper buttock the area will be cleansed with an antiseptic solution. Lidocaine or other local anesthetic will then be infiltrated into the biopsy area by injection to provide local anesthesia. A single 2 mm piece of skin will be removed via punch biopsy. A sterile gauze pad will be placed over the site to control bleeding, and the site will be bandaged. The biopsy site may be closed with a stitch if desired. The participant (and/or their parent) will be provided with post-biopsy care instructions.
1. **Institutional Review Board (IRB) website Main Page** – begin here

2. **Do You Need IRB Review?**

3. **Start with the definition of Human Subject’s Research:**

   Human subjects research is any research or clinical investigation that involves human subjects.

   - **Research** is a systematic investigation, including research development, testing and evaluation, designed to develop or contribute to generalizable knowledge.

   **AND**

   - **A human subject** means a living individual about whom an investigator (whether professional or student) conducting research obtains information or biospecimens through intervention or interaction with the individual, and uses, studies, analyzes, or generates identifiable private information or identifiable biospecimens.

     **TIP:** To determine if your Quality Assessment / Improvement activity (QA / QI) activity requires IRB review, assess whether the activity is designed to develop or contribute to generalizable knowledge. For more information, visit: [QI projects vs. QI Research](#) or review the related [Quality Improvement (QI) Research vs. QI Projects](#) EQUIP Tips guidance document.

4. **For activities that DO NOT meet the definition human subject research,** UCI Researchers must submit a **Non-Human Subject’s Research Self-Determination** in the IRB submission and Management system [Kuali Research Protocols (KRP)](#) to register their research activity with the IRB prior to initiation:

   ![Submission Type](image)

5. **For activities that meet the criteria of human subjects research,** determine whether the research qualifies for **Exempt Self-Determination** (i.e., IRB review not required, but IRB registration is required).

   a. UCI allows self-determination for Exempt Categories 1-4i, with noted exceptions. If your activity appears to meet the criteria, submit an Exempt Self-Determination in KRP.

   b. For additional guidance on exempt self-determination and Exempt Categories, see UCI HRP Policy #12 starting on page 85 of the “**All HRP Policies**” document.

---

1 Activities designed to develop or contribute to generalizable knowledge are those activities designed to draw general conclusions, inform policy, or generalize outcomes beyond a single individual or an internal program (i.e., to elaborate, to be an important factor in identifying or expanding truths, facts, information that are universally applicable).
Do You Need IRB Review? A Quick-Start Guide

V 6.1 January 2023

6. For human subject research that does NOT qualify for Exempt Self-Determination, IRB review is required.
   a. Begin the IRB submission process with Determining the level of risk involved in your research.

   IRB Submission Summary Table:

<table>
<thead>
<tr>
<th>Non-Human Subjects Research (NHSR) Self-Determination</th>
<th>Exempt Self-Determination</th>
<th>Exempt Research that Requires IRB Approval</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOT Human Subject Research</td>
<td>Human Subject Research</td>
<td>UCI IRB Review Required</td>
</tr>
<tr>
<td>UCI IRB Review is NOT Required</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Administrative Determination Submission Required</td>
<td>IRB Protocol Submission Required</td>
<td></td>
</tr>
</tbody>
</table>

   - Activities may begin once the self-determination form is completed and submitted. The UCI IRB will not review or approve the submission.
   - The UCI IRB will not review or approve the submission.
   - The Education and Quality Improvement Program (EQUIP) will conduct routine quality assurance review of the submissions to ensure accuracy of the self-determinations.
   - Amendments are not necessary unless activity no longer qualifies for the self-determination. In that case, amend the submission in Kuali Research Protocols (KRP) to allow for IRB review OR submit a new study in KRP.
   - Existing self-determinations completed prior to the launch of KRP (September 2021) remain valid. Do not re-submit in KRP.

   7. All self-determinations and IRB applications must be submitted in Kuali Research Protocols (KRP):
      a. Review the “KRP User Guide” PRIOR to submission.
      b. Please carefully follow the guidance text and prompts in KRP, as the form will generate sections to completed based upon the responses given. Failure to complete requisite sections will result in the delay of IRB approval.
      c. When IRB Review is required, review the Protocol Preparation Checklist to ensure a complete submission.
8. **Submission Deadlines:**
   a. **Non-Human Subject’s Research / Exempt Self-Determinations** are NOT reviewed by the IRB and there are NO submission deadlines.
   b. **Exempt and Expedited IRB applications** are reviewed by a subcommittee of IRB members. There are no submission deadlines for Exempt and Expedited research as they are reviewed on a rolling basis **within 4-6 weeks of submission**.
   c. **Full Committee applications** are reviewed monthly. UCI has two biomedical IRBs and one Social/Behavioral IRB. See [HRP Calendar and Deadlines](#) for full Committee meeting dates and deadlines.

9. **IRB Review & Determinations:**
   a. The results of the IRB review can be found once logged into the protocol in **KRP**. For review status, refer to the “**Admin Details**” section of KRP for “project status” or “amendment status”
   b. Full Committee meeting results are posted by 3 pm, the afternoon of the meeting.
   c. Detailed information about IRB Committee review, determinations and considerations can be found in the **IRB Reviewer Desk Reference** document.
   d. The IRB reviews the application and makes a determination:
      - **A - Approval.** The approval letter and stamped approved documents are available in KRP within 3-5 working days. Research studies should not begin until stamped approval documents are released.
      - **M - Minor changes required.** IRB “Action Items” are available in KRP within 10 working days.
      - **T - Tabled for re-review.** The application requires significant clarifications and revisions. IRB “Action Items” are available in KRP within 10 working days.

10. Review your [post approval responsibilities](#)

11. **Stay Up to Date** on current news and updates by subscribing to the **IRB ListServ**. Please send a blank email to or-era-join@department-lists.uci.edu.

## Regulations:

- **OHRP:** [Exempt Review Categories](#)
- **OHRP:** [Expedited Review Categories](#)
- **OHRP:** [45 CFR 46.110](#)
- **FDA:** [21 CFR 56.110](#)

## UCI IRB Additional Guidance:

- [IRB FAQ](#)
- [IRB Forms](#)
- [IRB Policies](#)

## IRB Contact Information:

- [IRB Staff Contact Information](#)
- [IRB Staff Weekly Office Hours](#)
FAST FACTS
Human Research Protections
Office of Research

The Institutional Review Board (IRB)

Research involving human subjects must undergo prospective Review by the IRB. The IRB is charged with protecting the safety and welfare of human research subjects and ensuring compliance with federal agencies, state laws and UC/UCI policies. UCI holds an active Federalwide Assurance of Compliance with the Department of Health and Human Services. The UCI FWA is 00004071. The IRB is also registered as required by the Food and Drug Administration (FDA). The UCI IORG is 0000236.

The UCI IRB is accredited through the Consortium for Applied Research Ethics Quality (Care-Q), a collaboration between all UC campuses and Stanford. UCI was the first site to be a fully accredited via the Care-Q process.

There are five IRBs at UCI that handle all types of research; biomedical, social-behavioral and educational, non-compliance and an urgent IRB for critical reviews of patient care where prospective IRB review is required. UCI allows for the use of commercial IRBs, as well as reliance on other, non-UCI IRBs.

To ensure basic institutional issues are addressed all human subject research must submit through the UCI IRB first, regardless of the requested IRB of record.

IRB Members are appointed by the Vice Chancellor for Research who is the UCI Official responsible for the human research protections program. Some HRP Staff are also IRB members. The IRB Member Rosters and the most commonly requested information by study sponsors are all available on the HRP web page.

WHAT IS RESEARCH?
Research is defined as a systematic investigation, including research development, testing and evaluation, designed to contribute to generalizable knowledge.

WHAT IS A HUMAN SUBJECT?
Living Individual about whom an investigator conducting research:

1) Obtains information or biospecimens through intervention or interaction with the individual, and uses, studies, or analyzes the information or biospecimens or

2) Obtains, uses, studies, analyzes or generates individual private information or identifiable biospecimens.

irb@uci.edu 949-824-8170
HRP Web Page Submit to the IRB

THE HRP TEAM
Human Research Protections (HRP) work directly with Researchers and the IRB to help facilitate research. This includes the coordination of the single IRB review process and our education and quality improvement program (EQUIP). Many of our Team are Certified IRB Professionals.

All are here to help!